Crippled by 2 deaths, Zafgen says obesity drug cut weight in PhIII

John Carroll

With its clinical development program for a new in limbo following the unexplained of two patients, reported today that the troubled Phase III study hit its co-primary efficacy endpoints in treating a rare eating disorder.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS